Target intelligence / Profile preview

Eukaryotic 28S ribosomal RNA (28S rRNA) (28S rRNA)

Target
28S rRNA
Molecular classification
Ribosomal RNA, Ribozyme, Non-coding RNA
01

Overview

The eukaryotic 28S ribosomal RNA (rRNA) is the structural and catalytic core of the large (60S) ribosomal subunit in eukaryotic cells. It contains the peptidyl transferase center (PTC), a highly conserved ribozyme responsible for catalyzing peptide bond formation during translation (Polacek & Mankin, 2005, PubMed). The 28S rRNA is a critical target for various Ribosome-Inactivating Proteins (RIPs) such as ricin and Shiga toxins, which irreversibly depurinate the sarcin/ricin loop (SRL) to halt protein synthesis (Grela et al., 2019, Frontiers in Chemistry). Additionally, the PTC within the 28S rRNA is the binding site for the FDA-approved drug Omacetaxine mepesuccinate, which inhibits the initial step of protein elongation (Gandhi et al., 2014, Blood). While most antibiotics target bacterial ribosomes, the eukaryotic 28S rRNA is increasingly explored for targeted cancer therapies and as a marker for ribosomopathies (Sulima et al., 2017, British Journal of Cancer). Dysregulation of this target is associated with nucleolar stress and the activation of the p53 pathway, making it a significant focus in both toxicology and oncology. Therapeutic challenges include the high systemic toxicity of 28S rRNA inhibitors and the potential for immunogenicity when using toxin-conjugated antibodies.

Other names
28S rRNALarge subunit ribosomal RNALSU rRNA28S ribosomal RNA component of the 60S subunitRNA, 28S ribosomal
02

Mechanism of action

Inhibition of protein synthesis through the catalytic inactivation of the peptidyl transferase center or the site-specific depurination of the sarcin/ricin loop.

03

Biological functions

Protein synthesisPeptide bond formationTranslation elongationRibosome assembly
04

Disease associations

InfectionCancerRibosomopathyAutoimmune disorders
05

Safety considerations

High systemic toxicityOff-target cell deathImmunogenicity of toxin-based conjugatesVascular leak syndromeNarrow therapeutic window
06

Interacting drugs

Ricin

7 more in the full profile.

07

Biomarkers

p53 activationNucleolar stress markers28S/18S rRNA ratioRibosomal RNA fragmentation

Beyond the preview

Go deeper on Eukaryotic 28S ribosomal RNA (28S rRNA) (28S rRNA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eukaryotic 28S ribosomal RNA (28S rRNA) (28S rRNA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call